Enhanced FcRn-dependent transepithelial delivery of IgG by Fc-engineering and polymerization

详细信息    查看全文

• 作者：Stian Foss^a ; ^b ; Algirdas Grevys^a ; ^b ; Kine Marita Knudsen Sand^a ; ^b ; Malin Bern^a ; ^b ; Pat Blundell^e ; Terje E. Michaelsen^c ; ^d ; Richard J. Pleass^e ; Inger Sandlie^a ; ^b ; Jan Terje Andersen^a ; ^b ; ^{j.t.andersen@medisin.uio.no" class="auth_mail" title="E-mail the corresponding author}
• 关键词：FcRn ; pH-dependent binding ; IgG ; Fc-fusion ; Transcytosis ; Epithelial ; Mucosal barrier
• 刊名：Journal of Controlled Release
• 出版年：2016
• 出版时间：10 February 2016
• 年：2016
• 卷：223
• 期：Complete
• 页码：42-52
• 全文大小：1407 K

文摘

Monoclonal IgG antibodies (Abs) are used extensively in the clinic to treat cancer and autoimmune diseases. In addition, therapeutic proteins are genetically fused to the constant Fc part of IgG. In both cases, the Fc secures a long serum half-life and favourable pharmacokinetics due to its pH-dependent interaction with the neonatal Fc receptor (FcRn). FcRn also mediates transport of intact IgG across polarized epithelial barriers, a pathway that is attractive for delivery of Fc-containing therapeutics. So far, no study has thoroughly compared side-by-side how IgG and different Fc-fusion formats are transported across human polarizing epithelial cells. Here, we used an in vitro cellular transport assay based on the human polarizing epithelial cell line (T84) in which both IgG1 and Fc-fusions were transported in an FcRn-dependent manner. Furthermore, we found that the efficacy of transport was dependent on the format. We demonstrate that transepithelial delivery could be enhanced by Fc-engineering for improved FcRn binding as well as by Fc-polymerization. In both cases, transport was driven by pH-dependent binding kinetics and the pH at the luminal side. Hence, efficient transcellular delivery of IgG-based drugs across human epithelial cells requires optimal pH-dependent FcRn binding that can be manipulated by avidity and Fc-engineering, factors that should inspire the design of future therapeutics targeted for transmucosal delivery.